Latest Breaking News On - சிகிச்சை பதவி - Page 2 : comparemela.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axsome Therapeutics, Inc - AXSM - Press Release

The investigation concerns whether Axsome and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. On July 14, 2021, Axsome disclosed in a filing with the U.S. Securities and Exchange Commission “that it has been notified by the U.S. Food and Drug Administration (the ‘FDA’) that the FDA is rescinding the Company’s Breakthrough Therapy Designation for its AXS-12 product candidate for the treatment of cataplexy in narcolepsy, due to the FDA approving an additional drug product for the treatment of cataplexy in narcolepsy subsequent to granting AXS-12 Breakthrough Therapy Designation.” On this news, Axsome’s stock price fell $6.60 per share, or 10.41%, to close at $56.82 per share on July 14, 2021.

New yorkUnited statesFrance generalLos angelesAbrahaml pomerantzRoberts willoughbyExchange commissionAxsome therapeutics incDrug administrationCompany breakthrough therapy designationPomerantz firmAxsome therapeuticsBreakthrough therapy designationTherapy designationபுதியது யார்க்ஒன்றுபட்டது மாநிலங்களில்

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axsome Therapeutics, Inc - AXSM

Risk Disclaimer - By using this web site you agree to its terms and conditions. All materials, including but not limited to articles, directories, photos, lists, etc., on this website are the sole property of ForexTV or the respective copyright holders and are intended for informational/educational purposes using hypothetical and sometimes anecdotal illustrations. The unauthorized use of any and all materials is prohibited and restricted by copyright law. Any use of materials on this site must be approved in advance by ForexTV. Before deciding to invest in foreign exchange you should carefully consider your investment objectives, level of experience, and risk appetite. The possibility exists that you could sustain a loss of some or all of your initial investment and therefore you should not invest money that you cannot afford to lose. You should be aware of all the risks associated with foreign exchange trading, and seek advice from an independent financial advisor if you have any

New yorkUnited statesFrance generalLos angelesAbrahaml pomerantzRoberts willoughbyExchange commissionAxsome therapeutics incDrug administrationCompany breakthrough therapy designationPomerantz firmAxsome therapeuticsBreakthrough therapy designationTherapy designationபுதியது யார்க்ஒன்றுபட்டது மாநிலங்களில்

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axsome Therapeutics, Inc

Share this article Share this article NEW YORK, July 14, 2021 /PRNewswire/ Pomerantz LLP is investigating claims on behalf of investors of Axsome Therapeutics, Inc. ( Axsome or the Company ) (NASDAQ: AXSM). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The investigation concerns whether Axsome and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. On July 14, 2021, Axsome disclosed in a filing with the U.S. Securities and Exchange Commission that it has been notified by the U.S. Food and Drug Administration (the FDA ) that the FDA is rescinding the Company s Breakthrough Therapy Designation for its AXS-12 product candidate for the treatment of cataplexy in narcolepsy, due to the FDA approving an additional drug product for the treatment of cataplexy in narcolepsy subsequent to granting AXS-12 Breakthrough Therapy Designation.

New yorkUnited statesFrance generalLos angelesAbrahaml pomerantzRoberts willoughbyExchange commissionPrnewswire pomerantzAxsome therapeutics incDrug administrationCompany breakthrough therapy designationPomerantz firmAxsome therapeuticsBreakthrough therapy designationTherapy designationபுதியது யார்க்

» FDA Grants Breakthrough Therapy Designation to Alkeus Stargardt Disease Therapy

» FDA Grants Breakthrough Therapy Designation to Alkeus Stargardt Disease Therapy
globalgenes.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globalgenes.org Daily Mail and Mail on Sunday newspapers.

United statesLeonide saadAlkeus pharmaceuticalsDrug administrationBreakthrough therapyTherapy designationஒன்றுபட்டது மாநிலங்களில்திருப்புமுனை சிகிச்சைசிகிச்சை பதவி

Chikungunya: Valneva awarded Breakthrough Therapy Designation for vaccine candidate

Chikungunya: Valneva awarded Breakthrough Therapy Designation for vaccine candidate
outbreaknewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from outbreaknewstoday.com Daily Mail and Mail on Sunday newspapers.

Juan carlos jaramilloEuropean medicines agencyDrug administrationBreakthrough therapy designationTherapy designationCarlos jaramilloChief medical officerஜுவான் கார்லோஸ் ஜராமில்லோதிருப்புமுனை சிகிச்சை பதவிசிகிச்சை பதவிகார்லோஸ் ஜராமில்லோதலைமை மருத்துவ அதிகாரி